BioAstin® Natural Astaxanthin May Reduce Sarcopenia According to a Japanese Study
2009-04-15
-
Cyanotech Corporation
BioAstin Natural Astaxanthin has demonstrated effectiveness in clinical research in several areas closely associated with aging. Astaxanthin’s benefits have already been well documented in areas such as skin aging, cardiovascular health, eye & brain health and of course, as an anti-inflammatory for conditions such as rheumatoid arthritis, carpal tunnel syndrome, tendonitis, and joint soreness due to exercise.
A recent pre-clinical trial done in Japan with BioAstin in rodents* opens up a new area of interest for BioAstin as an anti-aging supplement. In this study, rats were given BioAstin at a low level of 0.004% of their daily feed for one year. Significant improvements in the treatment group were found including increased muscle weight as well as the muscle weight to body weight ratio. The researchers concluded that long term use of BioAstin may reduce age-related muscle atrophy. These results confirm a pre-clinical trial done in 2005 that demonstrated similar results.
The new study is further evidence that Astaxanthin is the ideal ingredient for anyone over 50 years of age. For more information or to discuss formulation ideas, please contact us at bcapelli@cyanotech.com or call 808.334.9415.
* Please note that this research, although done with BioAstin, was not sponsored by Cyanotech. Our policy at Cyanotech is that we do not engage in animal research; however, we report animal research done by others as a means to fully understand the potential benefits of BioAstin in human nutrition. Cyanotech Corporation, a world leader in microalgae technology, produces BioAstin® Natural Astaxanthin and Hawaiian Spirulina Pacifica®—all natural, functional nutrients that enhance human health and nutrition. Cyanotech's spirulina, FDA reviewed and accepted as Generally Recognized as Safe (GRAS) for use as a food ingredient, augments energy and immune response. BioAstin's benefits derive from its superior antioxidant activity and from its ability to support and maintain natural inflammatory response, enhancing skin, muscle and joint health. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology and distributes them to nutritional supplement, nutraceutical and cosmeceutical makers and marketers in more than 40 countries worldwide.
Cyanotech was the first microalgae company in the world to obtain ISO 9001:2000 certification. Our products are all natural and are pesticide and herbicide free. They are free of genetically modified organisms and are produced in accordance with current Good Manufacturing Processes.
www.cyanotech.com
|
|
|
Related Articles : Cyanotech Announces FY09 Q2 and First Six Months of Fiscal 2009 Results (2008-11-13) Cyanotech Corporation has announced financial results for the second quarter and first six months of fiscal 2009, ended September 30, 2008, reporting revenues for the second quarter of fiscal 2009 increased 26% to $3,274,000, compared to revenues of $2,604,000 for the second quarter of fiscal 2008. Gross profit for the second quarter was $1,378,000, with gross profit margin of 42%, compared to a gross profit of $768,000 and gross profit margin of 29% reported for the same quarter of the prior year. Net income for the second quarter was $163,000, or $0.03 per diluted share, compared to net loss of $344,000, or ($0.07) per diluted share for the second quarter of fiscal 2008. Cyanotech Announces Improved Hawaiian Spirulina Pacifica (2009-02-05) Cyanotech has announced improvements to their Hawaiian Spirulina Pacifica. Cyanotech Reports Results for FY09 Q3 and First Nine Months (2009-02-12) Cyanotech Corporation has announced their FY09 Q3 results, reporting revenues increased 28.6% to $3,553,000, compared to revenues of $2,763,000 for the third quarter of fiscal 2008. Gross profit for the third quarter was $1,566,000, with gross profit margin of 44.1%, compared to a gross profit of $353,000 and gross profit margin of 12.8% reported for the same quarter of the prior year. Net income for the third quarter was $514,000, or $0.10 per diluted share, compared to net loss of $594,000, or ($0.11) per diluted share for the third quarter of fiscal 2008.
|
|
|
|